Overview of Immune Therapies in Multiple Myeloma
CAR T-Cell Therapies
CAR T-cell therapies are a type of personalized immunotherapy where T cells are modified to target and kill myeloma cells.
Common agents:
Abecma (idecabtagene vicleucel)
Abecma®,generic name idecabtagene vicleucel, is an immune cell therapy where a patient’s own T cells are modified (autologous) and delivered as a one-time infusion. It is approved for use in adult patients with relapsed and refractory myeloma who have had two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Carvykti (ciltacabtagene autoleucel)
Carvykti®,generic name ciltacabtagene autoleucel, is a personalized (autologous) T-cell immune therapy delivered as a one-time infusion. It is approved for use in adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including an immunomodulatory agent and a proteasome inhibitor, and are refractory to lenalidomide. Carvykti is the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with myeloma as early as first relapse.
Resources:
IMWG Consensus Guidelines: Management of Car-T
Video: CAR T Therapy in Multiple Myeloma | Myeloma University
NLB White Paper: CAR-T THERAPY in Earlier Lines of Treatment of Multiple Myeloma
Bispecific Antibodies
Bispecific antibodies are a type of immunotherapy that binds to two different targets, bringing myeloma cells and immune cells together to facilitate the destruction of the cancer cells. Examples include-Teclistamab, Talquetamab, Elranatamab and Linvoseltamab.
Common agents:
Elrexfio (elranatamab-bcmm)
Elrexfio®, or elranatamab-bcmm, is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. The FDA granted accelerated approval of Elrexfio in August 2023 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Lynzoyfic (linvoseltamab-gcpt)
Lynzofic™ (also known as linvoseltamab-gcpt , the generic drug name) is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. In July 2025, the U.S. FDA granted accelerated approval of Lynozyfic for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Talvey (talquetamab)
Talvey®, also known as talquetamab, is indicated for adult patients with relapsed or refractory myeloma who have had at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Talvey is a bispecific monoclonal antibody with a novel target, GPRC5D.
Tecvayli (teclistimab-cqyv)
Tecvayli®, or teclistamab-cqyv, is indicated for adult patients with relapsed or refractory myeloma who have had at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Tecvayli is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
Resources:
IMWG Consensus Guideline: Management of Bispecifics
Video: Bispecifics in Multiple Myeloma | Myeloma University
NLB White Paper: BISPECIFIC ANTIBODIES: Efficacy, Safety, and Transition of Care Management
Explore Further Resources
Access our comprehensive database for detailed protocols and management strategies. Enhance your understanding and preparedness for critical care scenarios.